Antonella Perotti - Concepedia

Author

Antonella Perotti

Fondazione IRCCS Istituto Nazionale dei Tumori

Also Known As

A Perotti, A. Perotti, Ana Clara Esteves Perotti, Antonella Perotti

Publications

734

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori European Institute of Oncology Kantonsspital St. Gallen Humanitas University Sarah Cannon

About

Antonella Perotti is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	257
2	Pathology	5	5	166
3	Pharmacology	5	5	133
4	Immunology	3	3	61
5	Cancer Cell Biology	3	3	94

Antonella Perotti

Publications

555

Citations

H-Index

Page 1

	Year	Citations
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails Cristiana Sessa, Filippo de Braud, Antonella Perotti, Journal of Clinical Oncology	2005	164
Clinical and pharmacological phase I evaluation of Exherin™ (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours Antonella Perotti, Cristiana Sessa, Andrea Mancuso, Annals of Oncology N-cadherin-expressing Solid TumoursPharmacological PhaseMedicineSelective Anti-n-cadherin PeptidePathology	2009	72
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer Cristiana Sessa, Antonella Perotti, Cristina Noberasco, European Journal of Cancer Breast OncologyOncologyMedicinePharmacokinetic StudyPathology	2008	57
Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine Antonella Perotti, Alberta Locatelli, Cristiana Sessa, Journal of Clinical Oncology	2010	43
Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule Cristiana Sessa, Antonella Perotti, Anna Lladó, Annals of Oncology Weekly ScheduleTherapeutic Drug MonitoringMedicinal ChemistryMedicineClinical Pharmacology	2007	41
Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer Giacomo Grasselli, Lucia Viganò, Giuseppe Capri, Journal of Clinical Oncology	2001	41
Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors. Todd M. Bauer, Chia‐Chi Lin, Richard Greil, Journal of Clinical Oncology ImmunologyImmunoeditingImmunotherapeuticsTgf-β BlockadeImmunotherapy	2021	37
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors Todd M. Bauer, Armando Santoro, Chia‐Chi Lin, Journal for ImmunoTherapy of Cancer	2023	33
Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours Walter Fiedler, Herbert Stoeger, Antonella Perotti, ESMO Open	2018	17
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors Cristiana Sessa, Gianluca Del Conte, Alexandre Christinat, Investigational New Drugs MedicineMetronomic TherapyPharmacokinetic StudyPathologyAdvanced Solid Tumors	2013	15

Page 1